IOVA News and Press, Iovance Biotherapeutics Inc. From 08/30/23

2023-08-30 16:01:36 ET Summary Iovance Biotherapeutics, Inc. has a deep pipeline of cancer immunotherapies, but has faced delays and issues with duration of response. The company's lead asset, lifileucel, is being tested in multiple trials for different indications. Underwhelm...

2023-08-08 22:35:25 ET Iovance Biotherapeutics, Inc. (IOVA) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Sara Pellegrino – Senior Vice President, Investor Relations and Corporate Communications Fred Vogt – Interim Pres...

2023-08-08 16:17:18 ET Iovance Biotherapeutics press release ( NASDAQ: IOVA ): Q2 GAAP EPS of -$0.47 beats by $0.38 . Revenue of $0.24M. For further details see: Iovance Biotherapeutics GAAP EPS of -$0.47 beats by $0.38, revenue of $0.24M

FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 Preparing for Potential Commercial Launch of Lifileucel as First Approved TIL Therapy in 2023 Post...

2023-08-07 17:35:16 ET Iovance Biotherapeutics ( NASDAQ: IOVA ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, after market close. The consensus EPS Estimate is -$0.79 and the consensus Revenue Estimate is $5.38M. Over the last 3 months, EPS estim...

SAN CARLOS, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced oral and poster pr...

SAN CARLOS, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter 202...

SAN CARLOS, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the closing of an ...

2023-07-11 12:15:54 ET Summary Iovance Biotherapeutics has received positive feedback from the FDA for its IOV-LUN-202 trial, which may lead to accelerated approval of its TIL therapy for advanced NSCLC. Iovance strengthened its financial position with a public offering expected t...

2023-07-11 11:18:16 ET Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were down more than 8% as of 10:45 a.m. ET on Tuesday after the biotech announced a public stock offering. The stock is up more than 26% so far this year. Iovance specializes in tumor infiltrating lympho...